Merck (MRK) starts phase 2b/3 trial evaluating Tiespectus for the treatment of neovascular age-related macular degeneration

Merck's initiation of a phase 2b/3 trial for Tiespectus could bolster its position in the competitive ophthalmology market, particularly for neovascular age-related macular degeneration. This development may attract interest from both investors and analysts, as successful trial outcomes could lead to significant revenue potential and influence future sales projections. The market response will likely hinge on investor sentiment toward biopharma trials and the broader healthcare landscape in Europe and the U.S.